WEST PHARMACEUTICAL SERVICES INC

Listed Company

WSTCIK 0000105770NYSELarge AcceleratedSurgical & Medical Instruments & ApparatusPennsylvaniaFY ends Dec 31

Period

FY 2025

Revenue

$3.07B

Net Income

$493.70M

Total Assets

$4.27B

Equity

$3.18B

Shares Out

70.65M

Op. Cash Flow

$754.80M

WST$358.18+61.58% · past yearDBEQ Basic

Daily closing prices

Business

West Pharmaceutical Services manufactures technologically advanced containment and delivery systems for injectable drugs. Core products include primary proprietary packaging, stoppers, seals, syringe and cartridge components, drug delivery devices, and integrated solutions. The company also provides contract manufacturing, reconstitution systems, and analytical lab services to biologic, pharmaceutical, generic, diagnostic, and medical device companies. Operations span North America, South America, Europe, and Asia.

Summary from 10-K filed 2026-02-17

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net sales	3,074	2,893	2,950	2,887	2,832
Cost of goods and services sold	1,970	1,895	1,821	1,751	1,656
Gross profit	1,104	999	1,129	1,136	1,176
Research and development	74	69	68	59	53
Selling, general and administrative expenses	394	339	353	317	363
Other expense (income) (Note 16)	51	21	31	27	8
Operating profit	585	570	676	734	752
Interest expense	500,000	3	9	8	—
Interest income	−18	−20	−28	−5	−1
Other nonoperating expense (income)	1	1	−3	51	−4
Income before income taxes and equity in net income of affiliated companies	601	586	698	680	749
Income tax expense	122	108	122	115	107
Equity in net income of affiliated companies	−14	−15	−18	−21	−20
Net income	494	493	593	586	662
Basic (in dollars per share)	6.83	6.75	7.98	7.87	8.89
Diluted (in dollars per share)	6.79	6.69	7.88	7.73	8.67
Basic (in shares)	72	73	74	74	74
Diluted (in shares)	73	74	75	76	76

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	791	485	854	894	763
Accounts receivable, net	574	553	512	507	489
Inventories	444	377	435	415	378
Other current assets	169	124	136	103	112
Total current assets	1,978	1,538	1,936	1,920	1,742
Property, plant and equipment	3,223	2,986	2,738	2,387	2,215
Less: accumulated depreciation and amortization	1,497	1,404	1,325	1,228	1,158
Property, plant and equipment, net	1,726	1,582	1,413	1,158	1,058
Operating lease right-of-use assets	117	105	99	104	69
Investments in affiliated companies	212	202	210	205	208
Goodwill	110	106	109	107	110
Intangible assets, net	8	11	15	18	23
Deferred income taxes	38	26	26	66	49
Other noncurrent assets	80	74	21	38	39
Total Assets	4,270	3,643	3,830	3,617	3,314
Accounts payable	254	239	242	215	232
Accrued salaries, wages and benefits	136	74	106	77	116
Income taxes payable	28	32	17	25	26
Operating lease liabilities	23	18	18	16	9
Other current liabilities	215	188	155	184	163
Total current liabilities	655	550	672	519	594
Long-term debt	203	203	73	207	209
Deferred income taxes	23	21	13	14	5
Pension and other postretirement benefits	29	28	30	28	41
Operating lease liabilities	96	82	85	93	63
Deferred compensation benefits	14	15	19	19	29
Other long-term liabilities	75	62	59	52	38
Total Liabilities	1,094	961	949	932	978
Commitments and contingencies (Note 18)	—	—	—	—	—
Preferred stock, 3.0 million shares authorized; 0.0 shares issued and outstanding in 2025 and 2024	0	0	0	0	0
Common stock, par value $0.25 per share; 200 million shares authorized; shares issued: 75.3 million in 2025 and 2024; shares outstanding: 72.0 million and 72.3 million in 2025 and 2024	19	19	19	19	19
Capital in excess of par value	0	22	120	232	249
Retained earnings	4,375	3,957	3,523	2,988	2,457
Accumulated other comprehensive loss	−106	−258	−144	−183	−160
Treasury stock, at cost (3.3 million and 3.0 million shares in 2025 and 2024)	−1,112	−1,057	−638	−371	—
Total Equity	3,176	2,682	2,881	2,685	2,335
Total Liabilities and Equity	4,270	3,643	3,830	3,617	3,314

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation	169	152	134	117	117
Amortization	3	4	4	4	5
Stock-based compensation	24	19	23	24	38
Non-cash restructuring charges	5	0	0	15	0
Pension settlement charges	0	0	100,000	52	2
Loss on disposal of plant	0	0	12	0	0
Asset impairments	12	7	10	6	6
Deferred income taxes	−14	−4	38	−31	−43
Pension and other retirement plans, net	600,000	−2	−3	−14	15
Equity in undistributed earnings of affiliates, net of dividends	−11	−13	−14	−18	−17
Other, net	−7	−5	1	−2	−1
Decrease (increase) in accounts receivable	7	−59	4	−36	−124
(Increase) decrease in inventories	−63	42	−14	−50	−87
Decrease (increase) in other current assets	10	−6	−21	19	−7
Increase in accounts payable	18	3	4	−3	17
Changes in other assets and liabilities	108	23	6	55	2
Net cash provided by operating activities	755	653	777	724	584
Capital expenditures	−286	−377	−362	−285	−253
Other, net	0	−2	−7	−4	3
Net cash used in investing activities	−286	−379	−369	−288	−253
Borrowings of long-term debt	0	165	0	0	—
Repayments of long-term debt	0	−169	−2	−44	0
Principal repayments on finance leases	−1	−23	−100,000	0	—
Dividend payments	−61	−59	−57	−54	−51
Excise tax payments	−4	−2	0	0	—
Proceeds from stock-based compensation awards	11	26	44	21	29
Employee stock purchase plan contributions	7	7	7	7	8
Shares purchased under share repurchase programs	−134	−561	−438	−203	−137
Shares repurchased for employee tax withholdings	−3	−6	−13	−19	−15
Net cash used in financing activities	−185	−623	−460	−294	−168
Effect of exchange rates on cash	23	−21	11	−11	—
Net increase (decrease) in cash and cash equivalents	307	−369	−40	132	147
Interest paid, net of amounts capitalized	300,000	500,000	6	7	8
Income taxes paid, net	125	71	91	110	172
Accrued capital expenditures	38	53	53	33	41

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is WEST PHARMACEUTICAL SERVICES INC's CIK number?

WEST PHARMACEUTICAL SERVICES INC's SEC CIK number is 0000105770 (105770). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find WEST PHARMACEUTICAL SERVICES INC's SEC filings?

All of WEST PHARMACEUTICAL SERVICES INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did WEST PHARMACEUTICAL SERVICES INC last report earnings?

WEST PHARMACEUTICAL SERVICES INC (WST) most recently filed an earnings 8-K with the SEC on Apr 23, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0000105770-26-000047). This is WEST PHARMACEUTICAL SERVICES INC's most recent earnings filing of record — not a forecast of its next earnings date.

What is WEST PHARMACEUTICAL SERVICES INC's most recent earnings 8-K?

WEST PHARMACEUTICAL SERVICES INC's latest earnings 8-K (Item 2.02) was filed Apr 23, 2026 under accession 0000105770-26-000047. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View WEST PHARMACEUTICAL SERVICES INC's latest earnings 8-K →
Look up any company's CIK number →